AptarGroup (NYSE:ATR) Stock Price Breaks Above 200-Day Moving Average - Here's Why

Key Points

• AptarGroup shares moved above their 200-day moving average, reaching $127.68 and last trading near $127.21, signaling improved technical momentum.
• Analysts maintain a favorable outlook, with a consensus rating of “Moderate Buy” and an average price target of $164.14; recent targets range from $150 to $173.
• The company exceeded quarterly earnings and revenue expectations, though insiders sold $3.13 million of stock over the past three months.

AptarGroup, Inc. (NYSE:ATR - Get Free Report) crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $126.83 and traded as high as $127.68. AptarGroup shares last traded at $127.2090, with a volume of 370,663 shares trading hands.

Analyst Ratings Changes

Several brokerages have recently weighed in on ATR. Deutsche Bank Aktiengesellschaft initiated coverage on shares of AptarGroup in a report on Wednesday, October 7th. They set a "buy" rating and a $150.00 price objective on the stock. Wells Fargo & Company upped their price target on shares of AptarGroup from $145.00 to $155.00 and gave the stock an "overweight" rating in a research report on Monday, August 3rd. Bank of America raised shares of AptarGroup from a "neutral" rating to a "buy" rating and set a $173.00 price target on the stock in a research note on Tuesday, July 14th. Raymond James Financial reissued an "outperform" rating and set a $160.00 price objective on shares of AptarGroup in a research note on Wednesday, July 15th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of AptarGroup in a research note on Monday, September 21st. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, AptarGroup has a consensus rating of "Moderate Buy" and a consensus target price of $164.14.

AptarGroup Stock Up 0.5%

The stock has a fifty day moving average price of $126.13 and a 200-day moving average price of $126.83. The firm has a market cap of $8.09 billion, a PE ratio of 23.00, a PEG ratio of 3.92 and a beta of 0.34. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.10 and a current ratio of 1.61.

AptarGroup (NYSE:ATR - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The industrial products company reported $1.42 earnings per share for the quarter, beating analysts' consensus estimates of $1.35 by $0.07. AptarGroup had a net margin of 9.22% and a return on equity of 13.31%. The firm had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same period in the previous year, the company posted $1.66 earnings per share. AptarGroup's revenue was up 6.3% compared to the same quarter last year. AptarGroup has set its Q3 2026 guidance at 1.450-1.530 EPS. Research analysts expect that AptarGroup, Inc. will post 5.47 EPS for the current year.

Insider Buying and Selling

In other AptarGroup news, CEO Gael Touya sold 3,740 shares of the firm's stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $133.76, for a total value of $500,262.40. Following the transaction, the chief executive officer directly owned 29,102 shares of the company's stock, valued at $3,892,683.52. This trade represents a 11.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Hedi Tlili sold 8,854 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $135.00, for a total value of $1,195,290.00. Following the completion of the sale, the insider owned 15,379 shares of the company's stock, valued at approximately $2,076,165. This trade represents a 36.54% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 23,197 shares of company stock valued at $3,134,828. 0.73% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Parkside Financial Bank & Trust increased its stake in shares of AptarGroup by 41.9% in the second quarter. Parkside Financial Bank & Trust now owns 298 shares of the industrial products company's stock valued at $37,000 after buying an additional 88 shares in the last quarter. State of Wyoming raised its position in shares of AptarGroup by 4.5% during the 1st quarter. State of Wyoming now owns 2,252 shares of the industrial products company's stock valued at $284,000 after acquiring an additional 98 shares during the last quarter. Crossmark Global Holdings Inc. increased its holdings in AptarGroup by 1.8% in the third quarter. Crossmark Global Holdings Inc. now owns 5,636 shares of the industrial products company's stock valued at $683,000 after purchasing an additional 99 shares during the last quarter. Steph & Co. raised its position in shares of AptarGroup by 11.5% in the 3rd quarter. Steph & Co. now owns 1,039 shares of the industrial products company's stock valued at $126,000 after acquiring an additional 107 shares during the period. Finally, Elevation Wealth Partners LLC raised its holdings in AptarGroup by 25.5% in the third quarter. Elevation Wealth Partners LLC now owns 546 shares of the industrial products company's stock worth $66,000 after purchasing an additional 111 shares during the period. 88.52% of the stock is owned by institutional investors and hedge funds.

AptarGroup Company Profile

AptarGroup, Inc NYSE: ATR develops and manufactures dispensing, sealing and delivery systems for the pharmaceutical, beauty, personal care, food and beverage markets. Its products are designed to control, protect and dispense a wide range of liquids, creams, lotions, fragrances and other formulations.

The company's offerings include pumps, valves, closures, aerosol systems and other dispensing components, as well as drug-delivery technologies. Through its pharmaceutical business, Aptar supports nasal, pulmonary, ophthalmic, dermal and injectable applications, serving pharmaceutical and biotechnology companies with components and systems used in prescription, over-the-counter and consumer health products.

Aptar serves customers internationally through manufacturing, research and development and commercial operations across North America, Europe, Asia and other global markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.